CSL Limited
CSL
Rangering i aksjer
#363
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Aksjekurs
$138.45
Markedsverdi
$66.44B
Endring (1 dag)
0.62%
Endring (1 år)
-2.39%
Land
AU
Handel CSL Limited (CSL)
Kategori
Healthcare
Antall utestående aksjer for CSL Limited (CSL)
Antall utestående aksjer per June 2026: 478.91M
Ifølge CSL Limited sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 478.91M. Ved slutten av June 2024 hadde selskapet 483.01M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for CSL Limited (CSL) fra 2000 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 478.91M | -1.03% |
| 2025 | 483.88M | 0.18% |
| 2024 | 483.01M | 0.17% |
| 2023 | 482.17M | 2.86% |
| 2022 | 468.76M | 3.05% |
| 2021 | 454.87M | 0.23% |
| 2020 | 453.81M | 0.20% |
| 2019 | 452.92M | 0.13% |
| 2018 | 452.35M | -0.65% |
| 2017 | 455.33M | -1.44% |
| 2016 | 462.00M | -2.08% |
| 2015 | 471.82M | -2.48% |
| 2014 | 483.82M | -2.97% |
| 2013 | 498.61M | -3.97% |
| 2012 | 519.23M | -3.94% |
| 2011 | 540.53M | -4.63% |
| 2010 | 566.78M | -4.78% |
| 2009 | 595.24M | 8.21% |
| 2008 | 550.11M | 0.44% |
| 2007 | 547.71M | 0.30% |
| 2006 | 546.08M | -7.12% |
| 2005 | 587.97M | 10.00% |
| 2004 | 534.52M | 11.94% |
| 2003 | 477.51M | 0.53% |
| 2002 | 474.99M | 5.89% |
| 2001 | 448.57M | 12.11% |
| 2000 | 400.11M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | -46.98% |
US
|
|
| 396.00M | -17.31% |
US
|
|
| - | - |
CH
|
|
| 62.19M | -87.02% |
NL
|
|
| 0.00 | -100.00% |
BE
|
